

## ONCO Emergence Forum

Montpellier, 14<sup>th</sup> and 15<sup>th</sup> December, 2017<https://emergence-forum-onconet.b2match.io/>Summary of participants – ONCO Emergence Forum, Montpellier, 14-15 December 2018:**Number of registrations: 153****Number of people attending the event: 121\*** (\*of which 20 had not registered online)**Number of B2B participants: 80****Country of origin of participants:**

- France: 99
- Espagne: 36
- Portugal: 12
- Royaume-Uni: 2
- Autriche: 1
- Luxembourg: 1
- Suisse : 1

**Types of organisations of origin:**

- University research centres and hospitals: 35
- Private companies: 52
- R&D Institutions: 35
- Association/Agency: 15
- Authority/government: 8
- Other: 7

**Participating universities (including university hospitals and research centres):**

- Université Toulouse III-Paul Sabatier, France
- Hospital Universitario Puerta de Hierro, Spain
- Biophysics Insitute, Faculty of Medicine of the University of Coimbra, Portugal
- Université de Montpellier, France
- IBBM, Université de Montpellier, France
- Insitute of biomedical Imaging and Life Sciences, Faculty of Medicine, University of Coimbra, Portugal

- Medical Genetic Department and CIMAGO from the Faculty of Medicine of Coimbra, Portugal
- Laboratory of CardioVascular Pharma-Ecology (LaPEC), University of Avignon, France
  - University of Granada, Spain
  - Ecole Nationale Supérieure Chimie Montpellier, France
  - Hospital del Mar Medical Research Institute (IMIM) and the Department of Experimental and Health Sciences of the Universitat Pompeu Fabra, Spain
  - Instituto Superior de Ciências da Saúde Egas Moniz, Portugal
  - University of Barcelona, Spain
  - University of Porto, Portugal
  - Centre de Recherche de Cancérologie de Toulouse, France

#### Participating private companies:

- |                             |                                     |
|-----------------------------|-------------------------------------|
| - DestiNA Genomics Ltd      | - Anaxomics Biotech                 |
| - Thermo Fisher Scientific  | - Papearus                          |
| - Prestizia                 | - SR Conseil                        |
| - Research trial            | - StartingBloch                     |
| - MERCK                     | - Biotech Développement et Conseils |
| - Oxeltis                   | - SeqOne                            |
| - ACOBIOM                   | - B2Match                           |
| - NanoMedSyn                | - ACOBIOM                           |
| - SOPHiA GENETICS           | - GoodGut SL                        |
| - Cell Constraint et Cancer | - Coral Biome                       |
| - OGD2 Pharma               | - Phost'in                          |
| - Vaiomer                   | - Tebu-bio                          |
| - Oncodieta                 | - Egenomics                         |
| - EMERCell                  | - Institut Roche                    |
| - SATT AxLR                 | - iMAb                              |
| - Concep trial              | - DIAG2TEC SAS                      |
| - Vita Api                  | - Era7 Bioinformatics               |
| - BioCytex                  | - Centre CAP                        |
| - ID Solutions              | - ICM                               |
| - AGV Discovery             |                                     |

**Participating Research and Development institutions:**


- Spanish National Cancer Research Centre
- Findmed
- Institut de Recerca Germans Trias i Pujol
- INSERM
- IPATIMUP
- Navarrabiomed
- IGMM, CNRS
- Centaur Clinical Research
- Barcelona Supercomputing Center
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
- Imdea Food Institute
- CNRS
- Institut Català d'Oncologia-IDIBELL
- IDIBAPS
- CHU Montpellier
- Institut d'Investigació Biomèdica de Girona Doctor Josep Trueta

**Participating associations/agencies:**

- Eurobiomed
- Biocat, BioRegion of Catalonia
- Transferts
- Cancer-Bio-Santé
- Invest Sud de France

**Participating authority/governmental organisations:**

- Institut de Recherche de Cancérologie de Montpellier
- Dirrecte Occitanie
- INRA
- Cancéropôle Grand Sud-Ouest
- IBBL
- CRCT, INSERM UMR 1037
- IBMM UMR5247



**Other participating bodies:**

- Granada Health Technology Park Foundation
- APHM- Timone II
- Roche-Chus Joint Unit
- Institut régional de Cancérologie de Montpellier – DRCI
- SIRIC Montpellier Cancer- ICM
- ICM
- IGF